Form 4: Fulgent Genetics CSO Sells Shares for Tax Obligations

Fulgent Genetics' Chief Scientific Officer, Hanlin Gao, sold 1,063 shares of common stock at a weighted-average price of $22.0267 to cover tax withholding obligations from RSU vesting.

Summary

• Chief Scientific Officer Hanlin Gao of Fulgent Genetics, Inc. sold 1,063 shares of the company's common stock.
• The transaction occurred on September 3, 2025, at a weighted-average price of $22.0267 per share, with individual sales ranging from $21.92 to $22.175.
• The purpose of the sale was to satisfy tax withholding obligations that arose upon the vesting of restricted stock units (RSUs) granted to Mr. Gao on February 28, 2022.
• This transaction was executed pursuant to a Rule 10b5-1 plan, indicating it was a pre-planned sale.
• Following this transaction, Mr. Gao beneficially owns 957,085 shares of Fulgent Genetics common stock directly.

Sentiment

Score: 6

Explanation: The transaction is a routine sale by an executive to cover tax obligations upon RSU vesting, executed under a Rule 10b5-1 plan. This is a common and expected event and does not typically signal a change in the executive's confidence in the company.

Positives

• The sale was for tax withholding obligations related to RSU vesting, indicating the executive is realizing value from previously granted equity compensation.
• The transaction was pre-planned under a Rule 10b5-1 plan, which suggests it is not a discretionary sale based on new, non-public information.

Negatives

• An insider sale, even for tax purposes, reduces the executive's direct ownership in the company.

Future Outlook

This Form 4 filing is a report of a past transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives receiving equity compensation. It does not inherently reflect broader industry trends or specific developments within the genetics or diagnostics sector.

Comparison to Industry Standards

• Insider sales for tax withholding upon RSU vesting are standard practice for executives in publicly traded companies across various industries, including biotechnology and diagnostics, such as Illumina (ILMN) or Guardant Health (GH).
• The use of a Rule 10b5-1 plan for such transactions is also a common corporate governance practice to mitigate concerns about insider trading, aligning with best practices observed in companies like Exact Sciences (EXAS) or Natera (NTRA).

Stakeholder Impact

• Shareholders: The sale of 1,063 shares represents a negligible amount relative to the company's total outstanding shares, resulting in minimal, if any, dilution or direct impact on shareholder value. The transaction is a routine part of executive compensation.

Key Dates

Recommendation

This Form 4 details a routine, pre-planned insider sale by the Chief Scientific Officer to cover tax obligations arising from RSU vesting. Such transactions are common and do not typically indicate a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

Fulgent Genetics, FLGT, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Hanlin Gao, Chief Scientific Officer, Rule 10b5-1